{"filings":[{"id":1138320,"accession_number":"0001193125-26-275815","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K/A","filed_at":"2026-06-18T20:06:18+00:00","items":["2.05","5.02"],"status":"ready","headline":"enGene cuts workforce 50%, grants CEO performance options tied to detalimogene BLA and FDA approval milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~50% approved June 14; estimated cash restructuring costs $5.7-6.4M, non-cash stock comp $4.7-5.0M.","Performance-based equity retention awards (options and RSUs) approved June 16, vesting upon FDA acceptance of detalimogene BLA (by Sep 30, 2027) and FDA approval (by Dec 31, 2028).","CEO Ronald Cooper granted 400,000 performance-based options at $1.75/share, vesting 50% per milestone.","Retention costs: up to $1.7M cash and $2.8M non-cash stock comp.","Majority of expenses expected in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1040036,"accession_number":"0001193125-26-270384","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2026-06-15T13:14:40+00:00","items":["2.02","2.05","5.02","7.01","8.01","9.01"],"status":"ready","headline":"enGene cuts workforce ~50%, CMO and CFO resign; Q2 loss widens to $30.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~50% to streamline ops and preserve cash; restructuring costs est. $5.7-$6.4M cash plus $4.7-$5.0M non-cash stock comp.","CFO Ryan Daws to depart July 15, 2026; Kathleen Richton appointed SVP Finance and principal financial officer.","CMO Dr. Hussein Sweiti resigned effective June 14; Dr. William Grossman named interim CMO.","Q2 net loss $30.2M ($0.43/share) vs $25.8M ($0.51/share) YoY; cash, equivalents and marketable securities $285.2M.","LEGEND Cohort 1: 54% CR at any time; awaiting 12-month durability data; BLA filing and FDA meeting planned for 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":972837,"accession_number":"0001193125-26-265830","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2026-06-10T20:09:58+00:00","items":["5.07","9.01"],"status":"ready","headline":"enGene shareholders re-elect all four directors, ratify auditor at 2026 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["56,196,302 common shares voted (83.89% of outstanding) at June 9, 2026 AGM.","All four director nominees elected with >99% votes cast in favor; broker non-votes ~8.8M.","Auditor appointment and remuneration approved: 56,180,287 for, 16,015 against.","No other significant proposals; no change in board composition or auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97048,"accession_number":"0001193125-26-210316","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"enGene reports 54% CR at any time in Phase 2 LEGEND trial; 43% CR at 6 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["54% complete response (CR) at any time (67/124) and 43% CR at 6 months (52/121) in BCG-unresponsive NMIBC with CIS.","Progression to muscle-invasive disease was low at 3.2%; Kaplan-Meier 12-month CR rate estimate is 25%.","Safety profile favorable: 55% treatment-related adverse events, mostly Grade 1-2; 2.4% led to discontinuation.","Company plans continued FDA engagement for BLA; data to be presented at AUA on May 15; update expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97047,"accession_number":"0001193125-26-149597","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"enGene Holdings changes name to enGene Therapeutics Inc., signals commercial readiness for detalimogene","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change to enGene Therapeutics Inc. effective April 8, 2026; tickers ENGN/ENGNW unchanged.","BLA submission for detalimogene planned for 2H 2026 in BCG-unresponsive NMIBC with CIS.","Potential approval and commercial launch targeted for 2027.","New CUSIP numbers: common shares 29286X101, warrants 29286X119."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111505,"accession_number":"0001193125-26-097546","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"enGene enters $100M at-the-market equity facility with Leerink Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Sales Agreement with Leerink Partners for up to $100M in common shares via at-the-market offerings.","Prior Open Market Sale Agreement with Jefferies LLC terminated on March 6, 2026; no shares sold and no penalties.","Leerink will receive a commission of up to 3.0% of gross proceeds; Company may reimburse certain expenses.","Shares will be sold under Rule 415(a)(4); Company not obligated to sell any shares.","No shares offered or sold in Canada under the new agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111504,"accession_number":"0001193125-26-097534","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"enGene Q1 net loss $29.8M; cash $312.5M; LEGEND data update at spring 2026 conference","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.8M ($0.44/share) vs $24.6M ($0.48/share) year ago; operating expenses $31.2M.","Cash & marketable securities $312.5M; expected runway into 2H 2028.","Expanded Hercules Capital debt facility to $125M for detalimogene development & commercial prep.","LEGEND pivotal cohort 63% CR at any time (n=62); BLA filing planned for 2H 2026.","12-month CR data expected 2H 2026; CDRP program selected by FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111503,"accession_number":"0001193125-26-017945","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"enGene expands loan facility to $125M; draws $25M initial tranche with Hercules Capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second Amendment increases term loan facility from $50M to up to $125M, with initial $25M advance to refinance prior debt.","New loans mature January 1, 2030; interest rate is prime + 2.25% (min 9.25%, capped at 10.25%).","End-of-term fee of 5.95% of aggregate principal; additional tranches tied to clinical, approval, and commercial milestones.","Issued 40,850 warrants at $9.18/share to Lenders as part of initial draw; up to 204,248 warrants possible if fully drawn.","Loan secured by substantially all assets including intellectual property; Hercules Capital acts as agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111502,"accession_number":"0001193125-26-017226","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"enGene expands debt facility with Hercules to $125M, $25M funded to refinance existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $125M debt facility from Hercules Capital; $25M funded at closing to refinance existing debt.","Three additional tranches up to $75M available upon achieving clinical, regulatory, and commercial milestones; final $25M at Hercules' discretion.","Maturity date January 1, 2030; proceeds support detalimogene BLA filing in H2 2026 and potential launch in 2027.","Non-dilutive capital strengthens balance sheet for planned BLA in BCG-unresponsive NMIBC with carcinoma in situ."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128130,"accession_number":"0001193125-25-328706","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"enGene FY2025 net loss $117.3M; LEGEND pivotal cohort complete (125 pts), 62% CR at 6 months; cash runway to 2H 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 net loss $117.3M ($2.29/sh) vs $55.1M ($1.46/sh) in 2024; R&D expenses up $56.2M to $123.2M total OpEx.","LEGEND pivotal cohort enrollment complete with 125 patients; preliminary CR rate 62% at 6 months (post-amendment patients).","Cash, equivalents, and marketable securities $202.3M at Oct 31, 2025; plus $140.1M net from Nov offering; runway into 2H 2028.","FDA selected enGene for CDRP program to support CMC readiness; BLA filing for detalimogene planned for 2H 2026.","Appointed Dr. Hussein Sweiti as CMO in September; he previously led J&J's bladder cancer portfolio leading to FDA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":2.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128129,"accession_number":"0001193125-25-283182","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"enGene prices $130M public offering of common shares and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing of 12,558,823 common shares at $8.50/share and pre-funded warrants for 2,735,295 shares at $8.4999 each.","Gross proceeds expected ~$130M before underwriting discounts and expenses.","Underwriters granted 30-day option to purchase up to 2,294,117 additional common shares.","Offering expected to close on or about November 14, 2025.","Proceeds to advance clinical-stage genetic medicines pipeline, including lead NMIBC candidate detalimogene."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128128,"accession_number":"0001193125-25-275722","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Detalimogene 62% CR at 6 months; primary endpoint changed; BLA on track H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Post-protocol amendment patients achieved 62% CR at 6 months (n=37) and 63% at any time (n=62).","Primary endpoint for pivotal cohort changed to CR at any time following FDA discussions; duration of response is key secondary.","BLA submission for detalimogene planned in H2 2026; potential FDA approval in 2027.","Cash, cash equivalents and short-term investments of $202.4M as of Oct 31, 2025.","Safety: 42% patients had TRAEs, mainly Grade 1/2; no Grade 4/5; dose interruptions 1.6%, discontinuations 0.8%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128127,"accession_number":"0001193125-25-228351","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2025-10-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"enGene amends CEO Ron Cooper's severance to 1.5x target bonus on change-in-control termination","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment to Cooper Employment Agreement, effective October 2, 2025.","CIC termination severance multiplier increased from 1.0x to 1.5x annual target bonus.","Lump sum payment payable within 45 days of CIC termination, subject to compliance.","Amendment recommended by Compensation Committee; full text to be filed in 10-K for FY ending Oct 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128126,"accession_number":"0001193125-25-228331","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K/A","filed_at":"2025-10-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"enGene Holdings appoints Astley-Sparke and Heffernan to board committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Philip Astley-Sparke appointed to Audit Committee and Nominating & Corporate Governance Committee.","Michael Heffernan appointed to Audit Committee and Compensation Committee.","Committee assignments effective October 2, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144914,"accession_number":"0001193125-25-224053","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"enGene appoints Dr. Hussein Sweiti as CMO; former J&J bladder cancer lead","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Sweiti appointed Chief Medical Officer effective September 29, 2025.","Previously Global Medical Head, Oncology at J&J; led bladder cancer portfolio and recent FDA NMIBC approval.","Will oversee global clinical development for detalimogene; BLA submission planned for 2H 2026.","Brings 15+ years experience in surgical oncology, drug development, and regulatory submissions.","Appointed after target enrollment reached in pivotal detalimogene NMIBC trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144913,"accession_number":"0000950170-25-114220","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"enGene Q3 net loss $28.9M; hits LEGEND enrollment target, RMAT designation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and marketable securities $224.9M; net loss $28.9M ($0.57/share) vs $14.1M ($0.32/share) YoY.","Achieved target enrollment of 100 patients in LEGEND pivotal cohort; data update expected 4Q 2025.","Detalimogene granted FDA RMAT designation; BLA submission planned for 2H 2026.","Operating expenses $29.9M, up from $16.8M; R&D costs increased $11M on LEGEND manufacturing and clinical costs.","Board appointed Philip Astley-Sparke, William Grossman, Michael Heffernan; promoted Matthew Boyd, Jill Buck, Katherine Chan."],"consensus_eps_estimate":null,"consensus_eps_actual":1.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144912,"accession_number":"0000950170-25-112674","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"enGene achieves target enrollment of 100 patients in Phase 2 LEGEND trial for detalimogene in BCG-unresponsive NMIBC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Target enrollment of 100 patients reached in Cohort 1 of Phase 2 LEGEND trial.","Trial evaluates detalimogene voraplasmid in high-risk, BCG-unresponsive NMIBC with CIS ± papillary disease.","Corporate presentation updated September 3, 2025; news release issued same day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144911,"accession_number":"0000929638-25-002520","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"enGene appoints Astley-Sparke, Grossman, Heffernan to board; promotes three executives","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Philip Astley-Sparke, William Grossman, Michael Heffernan appointed to Board effective July 8, 2025; Jasper Bos resigned.","Matthew Boyd promoted to Chief Regulatory Officer; Jill Buck to Chief Development Officer; Katherine Chan to Executive Director, Urology Clinical Lead.","New board members have experience in gene therapy, oncology, and product launches; company advancing detalimogene toward planned commercialization.","Board increased from seven to nine members after appointments; no disagreements cited for Bos resignation.","Independent director compensation plan applies; indemnification agreements entered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163300,"accession_number":"0000950170-25-085138","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"enGene Q2 loss $25.8M ($0.51/shr); cash $251.5M; LEGEND study on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.8M ($0.51/shr) vs $15.0M ($0.38) YoY; operating expenses $27.1M (up 57%).","Cash and marketable securities $251.5M expected to fund operations into 2027.","LEGEND pivotal cohort enrollment on track; BLA filing for detalimogene planned mid-2026.","EMA indicates data could support Conditional Marketing Authorization for BCG-unresponsive NMIBC.","Amy Pott appointed Chief Global Commercialization Officer effective May 2025."],"consensus_eps_estimate":-0.5081,"consensus_eps_actual":0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163299,"accession_number":"0000929638-25-002215","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve 2025 Employee Stock Purchase Plan; directors elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved the 2025 ESPP reserving 2,000,000 common shares for issuance.","Directors Gerald Brunk and Dr. Richard Glickman were elected with 30.5M and 26.3M for votes respectively.","ESPP effective June 10, 2025, allows eligible employees to purchase shares via payroll deductions.","Auditor appointment ratified with 38,101,229 votes in favor.","ESPP intended to qualify under Code Section 423; 74.6% of outstanding shares voted at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163298,"accession_number":"0000950170-25-083444","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"enGene signs 5-year lease for 26,335 sq ft Boston office; parent guarantees rent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease with 99 High Street Owner LLC for office at 99 High Street, Boston, MA (26,335 rentable square feet).","Initial term of 5 years 5 months, starting ~June 19, 2025; rent abated for first 5 months.","Monthly base rent starts at ~$168,982 (Year 1) and escalates to ~$182,912 (Year 5), plus operating expenses and taxes.","Parent enGene Holdings Inc. executed an unconditional guaranty of all Tenant obligations under the Lease.","Rentable area is 3.60% of Building; base year for operating expenses is 2026, taxes fiscal year 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163297,"accession_number":"0000929638-25-002133","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"enGene CMO Dr. Raj Pruthi resigns; effective June 16, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Raj Pruthi resigned as Chief Medical Officer; resignation date June 3, 2025.","He will support orderly transition of responsibilities before leaving on June 16, 2025.","No successor named; responsibilities reallocated to other urology and clinical experts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181236,"accession_number":"0000950170-25-036264","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"enGene Q1 net loss $24.6M ($0.48/sh); cash $272.8M; LEGEND on track for BLA mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $24.6M ($0.48 per share) for Q1 ended Jan 31, 2025, vs $10.7M ($0.46) a year ago.","Cash and marketable securities $272.8M; expected runway into 2027.","Total operating expenses $26.6M, up from $10.8M, driven by LEGEND study costs and headcount.","LEGEND pivotal cohort enrollment on track for BLA filing mid-2026; trial sites expanded to Europe/Asia.","Amended protocol adds maintenance dosing for patients in CR at 12 months up to 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198074,"accession_number":"0000950170-24-138767","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"enGene enters $100M ATM equity sale agreement with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Open Market Sale Agreement with Jefferies for ATM offering of common shares up to $100M.","Jefferies receives up to 3% commission; shares sold under prospectus supplement dated Dec 20, 2024.","Offering not available in Canada and company not obligated to sell any shares.","Agreement terminable by either party; proceeds for general corporate purposes not specified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198073,"accession_number":"0000950170-24-138446","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"enGene reports FY2024 net loss $55.1M; cash $297.9M; LEGEND study on track for mid-2026 BLA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $55.1M ($1.46/sh) vs $104.7M in FY2023; operating expenses $62.3M up from $26.1M.","Cash, cash equivalents and marketable securities $297.9M; expected to fund operations into 2027.","Preliminary LEGEND pivotal data: 71% anytime CR rate in BCG-unresponsive NMIBC with CIS; BLA filing on track for mid-2026.","First Amendment with Hercules Capital reallocates $7.5M to Tranche 3; total $50M facility unchanged.","Appointed Joan Connolly as CTO, Anthony Cheung as CSO, Alex Nichols as Chief Strategy & Operations Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198072,"accession_number":"0001193125-24-243481","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"enGene raises $60M via private placement of 6.76M shares at $8.90/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$60M from sale of 6,758,311 common shares at $8.90/share; expected close Oct 29, 2024.","Investors include Deep Track Capital, Cormorant Asset Management, Forbion, OrbiMed, Sphera Healthcare, Vestal Point Capital, Venrock Healthcare.","Net proceeds to fund detalimogene development, pre-commercial activities, DDX platform expansion, and working capital.","Combined with existing cash, expected to fund operating plan into 2027.","Leerink Partners, Piper Sandler, Guggenheim, Wells Fargo acted as placement agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198071,"accession_number":"0000950170-24-115767","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"enGene announces executive changes: new CTO, CSO, and President; Sullivan separation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joan Connolly appointed CTO effective Oct 21; brings 30+ yrs experience from Albireo, Stemline, Bristol-Myers.","Anthony Cheung transitions from CTO to CSO; James Sullivan departs Oct 31, 2024.","Sullivan separation agreement includes $485k salary continuation, prorated bonus, equity acceleration, option extension.","Alexander Nichols becomes Chief Strategy & Operations Officer; CEO Ron Cooper adds President title.","Detalimogene pivotal study ongoing; enGene expects BLA submission mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214220,"accession_number":"0000950170-24-109463","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Detalimogene shows 71% CR rate in LEGEND pivotal cohort; well-tolerated in BCG-unresponsive NMIBC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["71% complete response rate at any time (15/21 pts); 67% at 3 months; 47% at 6 months (8/17) in BCG-unresponsive NMIBC with Cis.","No drug-related discontinuations; TRAEs mostly Grade 1/2; two Grade 3 (peripheral edema, urosepsis); no Grade 4/5.","Median age 74; median 11 prior BCG doses; tumor stages: T1+Cis (14.3%), Ta+Cis (14.3%), Cis only (71.4%).","Company plans protocol refinements; conference call at 8:00 AM ET on Sept 26."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214219,"accession_number":"0000950170-24-105175","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"enGene Q3 net loss $14.1M; cash $257.7M; LEGEND data expected Sept 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.1M ($0.32/share) vs $6.0M prior year; operating expenses $16.8M (up from $6.2M).","Cash and equivalents $257.7M; expects runway into 2027.","Preliminary LEGEND study data (BCG-unresponsive NMIBC) due by end of September 2024.","Ron Cooper appointed CEO and board member; Dr. Raj Pruthi promoted to CMO in July 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214218,"accession_number":"0000950170-24-103727","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"enGene Holdings updates corporate presentation; no specific operational or financial changes disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation dated September 5, 2024 furnished as Exhibit 99.1.","Presentation titled 'Non-Viral Genetic Medicine' — no new pipeline or financial data provided in this filing.","No material events such as earnings, leadership changes, or financing announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214217,"accession_number":"0001193125-24-183292","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"enGene appoints Ron Cooper as CEO, promotes Raj Pruthi to CMO; Hanson departs as planned","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ron Cooper appointed CEO and director effective July 22, 2024; Jason Hanson resigns but remains as strategic advisor.","Cooper receives $700k base salary, 60% bonus target, and inducement option for 1.25M shares at $8.81, vesting over 4 years.","Raj Pruthi promoted to CMO succeeding Richard Bryce, who departed July 19, 2024.","Hanson's transition amendment provides $390k severance payment; retains consulting role at $25k/month for 6 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233456,"accession_number":"0000950170-24-073326","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"enGene Q2 net loss $15.0M; plans EG-70 trial expansion for papillary-only NMIBC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.0M ($0.38/share) vs $6.5M ($9.30/share) YoY; operating expenses $17.3M (up from $4.7M).","Cash and equivalents $264.8M; expects to fund operations into 2027.","Interim LEGEND cohort data (BCG-unresponsive ~20 patients) expected by end of Sep 2024; BLA mid-2026.","Plans to expand LEGEND with third cohort (70-100 patients) for papillary-only NMIBC, enrollment Q4 2024.","Deprioritized cystic fibrosis program EG-i08; Paul Hastings and Wouter Joustra elected to board."],"consensus_eps_estimate":null,"consensus_eps_actual":0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233455,"accession_number":"0000950170-24-060449","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"enGene Holdings shareholders approve amended 2023 Incentive Equity Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amended 2023 Incentive Equity Plan with 25,623,625 votes for and 2,586,367 against at May 15 annual meeting.","Plan amendment changes evergreen provision to annual increase of 5% of outstanding common shares (or smaller as determined by committee).","Directors Paul Hastings (28,201,063 for), Wouter Joustra (28,212,507 for), and Lota Zoth (28,212,007 for) elected.","Appointment of auditor approved with 28,467,217 votes for, no against or abstentions.","Amended plan filed as Exhibit 10.1; effective upon shareholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251536,"accession_number":"0000950170-24-029396","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"enGene Q1 net loss $10.7M; CEO to resign; $200M PIPE extends cash into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.7M ($0.46/share) vs $8.6M ($13.29/share) YoY; operating expenses $10.8M vs $4.6M.","Completed $200M oversubscribed PIPE (20M shares at $10, 31% premium); net proceeds $187.5M.","Cash $85.6M as of Jan 31; with PIPE proceeds, expects runway into 2027.","CEO Jason Hanson to resign upon appointment of successor; Board conducting search.","Pivotal Phase 2 LEGEND study for EG-70 in NMIBC on track; interim data mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251535,"accession_number":"0001193125-24-035074","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"enGene raises $200M via oversubscribed private placement; CEO Hanson to resign for family/health reasons","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 20M shares at $10.00 each (31% premium to Feb 13 close); gross proceeds $200M; expected close Feb 16.","New and existing investors participated, including Adage, Blue Owl, Boxer, Cormorant, Deerfield, and Janus Henderson.","Proceeds to fund EG-70 pivotal study for BCG-unresponsive NMIBC; cash runway extends into 2027.","CEO Jason Hanson to resign upon successor appointment due to personal family/health reasons; Board initiated search.","Hanson will serve as Senior Strategic Advisor for at least six months post-resignation at $25,000/month."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251534,"accession_number":"0000950170-24-008123","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2024-01-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"enGene reports FY2023 net loss $104.7M; Phase 1 LEGEND study 68% CR rate, interim data mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 net loss $104.7M ($151.22/share) vs $29.0M ($44.30) in FY2022; operating expenses $26.0M.","Phase 1 LEGEND study in BCG-unresponsive NMIBC met endpoints; 68% complete response at 3 months (n=22); pivotal Phase 2 enrolling, interim data mid-2024.","Completed reverse merger with FEAC and upsized PIPE financing, net proceeds ~$109M; launched on Nasdaq Nov 1, 2023.","Expanded Hercules debt facility to $50M ($22.5M funded); cash $81.5M at Oct 31, 2023, runway into Q2 2025.","Leadership hires: Alex Nichols (President/COO), Richard Bryce (CMO), Ryan Daws (CFO), Lota Zoth (Board)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269109,"accession_number":"0001193125-23-305161","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2023-12-28T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"enGene enters up to $50M term loan with Hercules Capital; draws $22.5M initially","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $50M term loan, initial $22.5M drawn, $8.6M refinances prior debt.","Interest: prime+0.75% (cap 9.75%) or 9.25% cash, plus 1.15% PIK.","Maturity Jan 1, 2028; interest-only until July 2025, extendable to Jan 2026 or Jul 2026 if milestones met.","Warrants to lenders for 2% of principal at $7.21 strike; 62,413 warrants issued initially.","Negative covenants restrict additional debt, liens, dividends, acquisitions, and IP sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269108,"accession_number":"0000929638-23-003464","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"enGene appoints Lota Zoth to Board as Audit Committee Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lota S. Zoth, CPA, appointed as Class I Director, effective Dec 18, 2023.","Zoth will serve as Audit Committee Chair; Board expanded from four to five members.","She brings 20+ years of financial and audit experience, including CFO at MedImmune.","Currently serves on boards of Lumos Pharma, Inovio Pharmaceuticals, and 89 Bio.","Standard independent director compensation plan applies; no related-party transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269107,"accession_number":"0000929638-23-003423","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"enGene appoints Ryan Daws as CFO with $440K salary, 232K stock option grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ryan Daws appointed CFO effective Nov 27, 2023; base salary $440,000, target bonus 40%.","One-time sign-on bonus of $143,500 payable Jan 2024; must repay if leaves within 1 year or terminated for cause.","Granted option for 232,000 common shares at fair market value on Nov 30, 2023; 25% vests on 1st anniversary, monthly thereafter.","Severance on termination without cause or for good reason: 12 months base salary, COBRA, prorated bonus, and partial equity acceleration.","On change in control termination: full equity acceleration plus 12 months base and target bonus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269106,"accession_number":"0000929638-23-003305","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2023-11-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"enGene appoints Ryan Daws as CFO and Head of Business Development; new CMO agreement with Richard Bryce","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ryan Daws appointed CFO and Head of Business Development, effective Nov 27, 2023; replaces Alexandre Grassin.","Daws receives $440K base salary, 40% bonus, $143.5K signing bonus, and 232,000 stock options vesting over 4 years.","CMO Richard Bryce enters employment agreement with $450K base, 40% bonus, eligibility for 153,000 stock options in 2024.","Bryce's agreement provides severance: 12 months base salary plus benefits upon termination or change in control.","enGene's lead program EG-70 in pivotal study for BCG-unresponsive NMIBC; interim data read-out expected mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269105,"accession_number":"0000929638-23-003066","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"enGene finalizes employment agreements with CEO, COO, CSO, CTO; salaries $450k-$590k","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Jason Hanson: $590k base, 55% annual bonus target, 12-month severance non-CIC, 18-month CIC.","COO Alex Nichols: $475k base, 40% bonus target, 12-month severance non-CIC, 12-month CIC.","CSO James Sullivan: $485k base, 40% bonus target, 12-month severance non-CIC, 12-month CIC.","CTO Anthony Cheung: $450k base, 40% bonus target, 18-month severance (non-CIC and CIC).","All agreements effective Nov 1, 2023; cover restrictive covenants, equity acceleration, and COBRA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269104,"accession_number":"0001193125-23-267243","cik":1980845,"company_name":"enGene Therapeutics Inc.","ticker":"ENGN","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["1.01","2.01","9.01","3.02","3.03","5.01","5.02","5.03","5.05","5.06"],"status":"ready","headline":"enGene closes business combination with SPAC Forbion European Acquisition Corp., becomes public on Nasdaq","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["New enGene shares and warrants trade on Nasdaq under 'ENGN' and 'ENGNW' starting Nov 1, 2023.","Approximately 10.4 million FEAC Class A shares were redeemed in connection with the deal.","Post-combination, Forbion Growth (31.9%), Lumira Ventures (14.4%), and others are top shareholders.","Company retains enGene's focus on non-viral gene therapies for mucosal tissues, lead candidate EG-70 for NMIBC.","PIPE financing was consummated alongside the transaction (amount not disclosed in this filing)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115221890.1590909,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}